Rabies Trial returns positive results

A Phase II clinical trial testing a vaccine with a treatment for rabies has turned out positive results. Read more here at FDA News.

The U.S. trial was set up as a single-blind, controlled study in 140 healthy volunteers to test the antibody in association with Sanofi Pasteur human diploid cell rabies vaccine.

All subjects completed the study, only mild-to-moderate adverse events were reported and the overall systemic safety was comparable with that of the placebo. The neutralizing activity against the rabies virus was comparable with that of standard care.